Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
NCT00652392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 750
Last updated 2011-01-24
Summary
The purpose of this study is to compare a dose of Symbicort taken once daily with other dosage regimens of Symbicort , budesonide and placebo for the treatment of asthma in adolescents and adults
Conditions
Interventions
- DRUG
-
budesonide/formoterol
- DRUG
-
budesonide and placebo
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Catherine Bonuccelli · AstraZeneca
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-04-30
- Completion
- 2004-06-30
More Related Trials
-
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
NCT01444430 ·Status: COMPLETED ·Phase: PHASE3
-
Gemini Symbicort pMDI
NCT00646516 ·Status: COMPLETED ·Phase: PHASE3
-
SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults
NCT00259792 ·Status: COMPLETED ·Phase: PHASE3
-
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
NCT02091986 ·Status: COMPLETED ·Phase: PHASE3
-
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
NCT01360021 ·Status: COMPLETED ·Phase: PHASE3
-
Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy
NCT00319306 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Symbicort on GR Localisation in Asthma
NCT00159263 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma
NCT00536913 ·Status: COMPLETED ·Phase: PHASE3
-
Phase4/Symbicort® Versus Pulmicort Flexhaler® in African Americans
NCT00702325 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
NCT02495168 ·Status: COMPLETED ·Phase: PHASE3
-
Symbicort in Asthmatic Children - SEEDLING
NCT00651547 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects
NCT00691951 ·Status: COMPLETED ·Phase: PHASE3
-
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma
NCT00252824 ·Status: COMPLETED ·Phase: PHASE3
-
Adults With Moderate to Severe Asthma
NCT00642122 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
NCT00651651 ·Status: COMPLETED ·Phase: PHASE3
-
SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults
NCT00238784 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
NCT00989833 ·Status: COMPLETED ·Phase: PHASE2
-
Symbicort Onset of Action 1
NCT00646620 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations
NCT01218399 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
NCT02149199 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations
NCT00272753 ·Status: COMPLETED ·Phase: PHASE4
-
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
NCT00235911 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety of Symbicort in Asthmatic Children - SAPLING
NCT00646529 ·Status: COMPLETED ·Phase: PHASE3
-
Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)
NCT00915538 ·Status: COMPLETED ·Phase: PHASE4
-
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
NCT00255255 ·Status: COMPLETED ·Phase: PHASE3